https://orcid.org/0000-0002-1823-0854
Overview
Dr. Liangbo (Linus) Shen is a vitreoretinal surgery fellow at Duke University School of Medicine. He graduated summa cum laude in Biomedical Engineering from Duke, where he co-invented a patented stereoscopic heads-up display system for ophthalmic surgery and advanced intraoperative optical coherence tomography. He went on to earn his medical degree cum laude from Yale School of Medicine, where he co-developed the “entry time realignment” statistical method that enabled long-term natural history studies of geographic atrophy, choroideremia, Stargardt disease, Huntington’s disease, and USH2A-retinopathy. He also identified novel imaging biomarkers and developed a pixel-based analysis method that can reduce clinical trial sample sizes for geographic atrophy by more than tenfold compared with conventional methods.
Dr. Shen completed rigorous clinical and surgical training during his ophthalmology residency at the University of California, San Francisco. At UCSF, he also pursued research in imaging biomarkers of age-related macular degeneration and inherited retinal degenerations. His work included leading analyses for the METforMIN randomized trial on metformin and geographic atrophy progression, investigating cone structure changes in choroideremia, and inventing a syringe attachment for one-handed anterior chamber paracentesis.
Now at Duke, Dr. Shen continues to refine pixel-based imaging analysis to improve trial efficiency and to evaluate treatment response in geographic atrophy and inherited retinal degenerations. He has authored or co-authored more than 50 peer-reviewed publications in high-impact journals including Ophthalmology, JAMA Ophthalmology, and the American Journal of Ophthalmology.
Dr. Shen has been recognized with numerous national awards, including the Heed Fellowship, AUPO/RPB Resident and Fellow Research Forum Award, and best research awards at conferences. He has delivered talks on his research at major national and international conferences, including ARVO, AAO, ASRS, and AUPO.
Deeply committed to advancing the understanding of retinal diseases, Dr. Shen integrates engineering, imaging, and clinical research to develop diagnostics and treatments that improve patient care.